Logo image of TSHA

TAYSHA GENE THERAPIES INC (TSHA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:TSHA - US8776191061 - Common Stock

5.05 USD
-0.01 (-0.2%)
Last: 12/5/2025, 8:00:01 PM
5.05 USD
0 (0%)
After Hours: 12/5/2025, 8:00:01 PM
Fundamental Rating

2

Overall TSHA gets a fundamental rating of 2 out of 10. We evaluated TSHA against 531 industry peers in the Biotechnology industry. While TSHA seems to be doing ok healthwise, there are quite some concerns on its profitability. TSHA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

TSHA had negative earnings in the past year.
In the past year TSHA has reported a negative cash flow from operations.
TSHA had negative earnings in each of the past 5 years.
In the past 5 years TSHA always reported negative operating cash flow.
TSHA Yearly Net Income VS EBIT VS OCF VS FCFTSHA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

TSHA has a better Return On Assets (-31.57%) than 66.36% of its industry peers.
Looking at the Return On Equity, with a value of -45.63%, TSHA is in the better half of the industry, outperforming 67.85% of the companies in the same industry.
Industry RankSector Rank
ROA -31.57%
ROE -45.63%
ROIC N/A
ROA(3y)-83.9%
ROA(5y)-71.29%
ROE(3y)-6239.76%
ROE(5y)-3785.22%
ROIC(3y)N/A
ROIC(5y)N/A
TSHA Yearly ROA, ROE, ROICTSHA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for TSHA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TSHA Yearly Profit, Operating, Gross MarginsTSHA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -2K -4K -6K

More info and screens

5

2. Health

2.1 Basic Checks

TSHA does not have a ROIC to compare to the WACC, probably because it is not profitable.
TSHA has more shares outstanding than it did 1 year ago.
TSHA has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, TSHA has a worse debt to assets ratio.
TSHA Yearly Shares OutstandingTSHA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
TSHA Yearly Total Debt VS Total AssetsTSHA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

An Altman-Z score of 5.47 indicates that TSHA is not in any danger for bankruptcy at the moment.
TSHA has a better Altman-Z score (5.47) than 74.02% of its industry peers.
A Debt/Equity ratio of 0.23 indicates that TSHA is not too dependend on debt financing.
The Debt to Equity ratio of TSHA (0.23) is worse than 68.04% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF N/A
Altman-Z 5.47
ROIC/WACCN/A
WACC8.81%
TSHA Yearly LT Debt VS Equity VS FCFTSHA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 10.48 indicates that TSHA has no problem at all paying its short term obligations.
TSHA's Current ratio of 10.48 is amongst the best of the industry. TSHA outperforms 82.62% of its industry peers.
TSHA has a Quick Ratio of 10.48. This indicates that TSHA is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of TSHA (10.48) is better than 82.62% of its industry peers.
Industry RankSector Rank
Current Ratio 10.48
Quick Ratio 10.48
TSHA Yearly Current Assets VS Current LiabilitesTSHA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for TSHA have decreased strongly by -152.38% in the last year.
TSHA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -36.36%.
EPS 1Y (TTM)-152.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10%
Revenue 1Y (TTM)-36.36%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

TSHA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 28.07% yearly.
The Revenue is expected to grow by 126.77% on average over the next years. This is a very strong growth
EPS Next Y-2.89%
EPS Next 2Y-12.26%
EPS Next 3Y-11.75%
EPS Next 5Y28.07%
Revenue Next Year-20.9%
Revenue Next 2Y-27.82%
Revenue Next 3Y43.99%
Revenue Next 5Y126.77%

3.3 Evolution

TSHA Yearly Revenue VS EstimatesTSHA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
TSHA Yearly EPS VS EstimatesTSHA Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

TSHA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TSHA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TSHA Price Earnings VS Forward Price EarningsTSHA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TSHA Per share dataTSHA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 0.6

4.3 Compensation for Growth

A cheap valuation may be justified as TSHA's earnings are expected to decrease with -11.75% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-12.26%
EPS Next 3Y-11.75%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TSHA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TAYSHA GENE THERAPIES INC

NASDAQ:TSHA (12/5/2025, 8:00:01 PM)

After market: 5.05 0 (0%)

5.05

-0.01 (-0.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04 2025-11-04/bmo
Earnings (Next)02-24 2026-02-24/amc
Inst Owners97.05%
Inst Owner Change2.03%
Ins Owners1.03%
Ins Owner Change-1.13%
Market Cap1.38B
Revenue(TTM)6.31M
Net Income(TTM)-99.93M
Analysts85.26
Price Target10.78 (113.47%)
Short Float %19.73%
Short Ratio7.1
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-4.52%
Min EPS beat(2)-9.04%
Max EPS beat(2)-0.01%
EPS beat(4)2
Avg EPS beat(4)5.88%
Min EPS beat(4)-9.04%
Max EPS beat(4)17.32%
EPS beat(8)5
Avg EPS beat(8)124.3%
EPS beat(12)7
Avg EPS beat(12)85.18%
EPS beat(16)9
Avg EPS beat(16)64.99%
Revenue beat(2)1
Avg Revenue beat(2)-39.34%
Min Revenue beat(2)-100%
Max Revenue beat(2)21.32%
Revenue beat(4)2
Avg Revenue beat(4)-10.09%
Min Revenue beat(4)-100%
Max Revenue beat(4)52.45%
Revenue beat(8)5
Avg Revenue beat(8)-3.64%
Revenue beat(12)8
Avg Revenue beat(12)34.16%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)8.21%
PT rev (3m)21.98%
EPS NQ rev (1m)-2.17%
EPS NQ rev (3m)-2.24%
EPS NY rev (1m)-3.33%
EPS NY rev (3m)-2.16%
Revenue NQ rev (1m)9.08%
Revenue NQ rev (3m)25.57%
Revenue NY rev (1m)-13.14%
Revenue NY rev (3m)-11.71%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 219.22
P/FCF N/A
P/OCF N/A
P/B 6.32
P/tB 6.32
EV/EBITDA N/A
EPS(TTM)-0.33
EYN/A
EPS(NY)-0.45
Fwd EYN/A
FCF(TTM)-0.31
FCFYN/A
OCF(TTM)-0.31
OCFYN/A
SpS0.02
BVpS0.8
TBVpS0.8
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -31.57%
ROE -45.63%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-83.9%
ROA(5y)-71.29%
ROE(3y)-6239.76%
ROE(5y)-3785.22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 42.26%
Cap/Sales 7.7%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.48
Quick Ratio 10.48
Altman-Z 5.47
F-Score3
WACC8.81%
ROIC/WACCN/A
Cap/Depr(3y)691.55%
Cap/Depr(5y)1199.42%
Cap/Sales(3y)284.78%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-152.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10%
EPS Next Y-2.89%
EPS Next 2Y-12.26%
EPS Next 3Y-11.75%
EPS Next 5Y28.07%
Revenue 1Y (TTM)-36.36%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-20.9%
Revenue Next 2Y-27.82%
Revenue Next 3Y43.99%
Revenue Next 5Y126.77%
EBIT growth 1Y-23.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-27.18%
EBIT Next 3Y40.3%
EBIT Next 5YN/A
FCF growth 1Y-76.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-100.7%
OCF growth 3YN/A
OCF growth 5YN/A

TAYSHA GENE THERAPIES INC / TSHA FAQ

What is the ChartMill fundamental rating of TAYSHA GENE THERAPIES INC (TSHA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to TSHA.


What is the valuation status of TAYSHA GENE THERAPIES INC (TSHA) stock?

ChartMill assigns a valuation rating of 0 / 10 to TAYSHA GENE THERAPIES INC (TSHA). This can be considered as Overvalued.


What is the profitability of TSHA stock?

TAYSHA GENE THERAPIES INC (TSHA) has a profitability rating of 1 / 10.


What is the financial health of TAYSHA GENE THERAPIES INC (TSHA) stock?

The financial health rating of TAYSHA GENE THERAPIES INC (TSHA) is 5 / 10.